UltraGreen ai (ULG) investor relations material

Executive summary

• Revenue grew 24% year-over-year to $87.2 million in 1H2026, driven by higher ICG vial sales, price increases, and market expansion in Europe, Asia, and the Americas.

• Net profit attributable to shareholders rose 53% to $39.2 million, with underlying NPAT before exceptional items up 45% to $39.4 million and net profit margin at 45%.

• Gross margin improved to 87% from 85% year-over-year, reflecting favorable pricing and geographic mix.

• Interim dividend of $0.01 per share declared, with a target of semi-annual dividends and payment scheduled for September 4, 2026.

• Regulatory approvals expanded for key products, with PerfusionWorks and quantification software on track for EU and US certification.

Financial highlights

• Gross profit increased up to 34% to $75.5 million, with cost of sales up 14% to $11.6 million.

• Adjusted EBITDA grew 16% to $52.5 million, with margin at 60%, while EBITDA increased 41% to $52.1 million.

• Operating profit reached $47.5 million, up 11% year-over-year.

• Basic EPS rose 53% year-over-year to 3.56 US cents.

• Cash and short-term investments grew 12% to $197.6 million as of June 30, 2026.

Outlook and guidance

• FY2026 revenue expected between $175 million and $185 million, with 2H2026 revenue projected to exceed 1H2026.

• Double-digit growth in both revenue and underlying net profit projected for FY2026.

• Net margin for 2H2026 anticipated to remain broadly stable.

• Growth to be sustained by market expansion, new procedure support, and regulatory progress for quantification software.

• Continued commitment to semi-annual dividends and share buybacks.